Skip to main content

Andrew Ellingsen represents clients in a variety of industries in antitrust and competition matters, including government review of mergers and acquisitions, filing obligations under the Hart-Scott-Rodino Act, complex civil litigation, and counseling clients in relation to antitrust issues.

Andrew received his J.D. from the University of Virginia School of Law, where he served at the Senior Review Editor of the Virginia Law & Business Review. Prior to law school, Andrew worked as an honors paralegal at the Federal Trade Commission, working on investigations and litigations involving mergers and anticompetitive practices. He received his Bachelors of Science from Duke University in Economics.


  • Pfizer in its $43 billion acquisition of Seagen Inc., a world-leader in antibody-drug conjugates (ADCs).



  • J.D., University of Virginia School of Law, 2020
  • B.S., Economics, Duke University, 2013


  • District of Columbia